Neurocrine Biosciences, Inc. reaffirmed sales guidance for the full year of 2024. For the year, company expects INGREZZA Net Product Sales of $2,100 million to $2,200 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.2 USD | -1.29% | -4.75% | +1.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.15% | 13.58B | |
+18.07% | 125B | |
+13.11% | 108B | |
-7.20% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-12.83% | 16.37B | |
+27.24% | 11.66B | |
+88.22% | 9.17B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024